SANGAMO THERAPEUTICS, INCSGMOEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.
SGMO Q4 FY2025 Key Financial Metrics
Revenue
$14.2M
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
88.4%
SANGAMO THERAPEUTICS, INC Q4 FY2025 Financial Summary
SANGAMO THERAPEUTICS, INC reported revenue of $14.2M (up 88.4% YoY) for Q4 FY2025, with a net profit of N/A (down 59.9% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $14.2M |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
SANGAMO THERAPEUTICS, INC Annual Revenue by Year
SANGAMO THERAPEUTICS, INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $39.6M).
SANGAMO THERAPEUTICS, INC Quarterly Revenue & Net Profit History
SANGAMO THERAPEUTICS, INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $14.2M | +88.4% | N/A | N/A |
| Q3 FY2025 | $581.0K | -98.8% | $-34.9M | -6012.0% |
| Q2 FY2025 | $18.3M | +5042.1% | $-20.0M | -109.2% |
| Q1 FY2025 | $6.4M | +1238.3% | $-30.6M | -475.3% |
| Q4 FY2024 | $7.6M | +269.8% | N/A | N/A |
| Q3 FY2024 | $49.4M | +425.8% | $10.7M | 21.6% |
| Q2 FY2024 | $356.0K | -94.8% | $-36.1M | -10148.3% |
| Q1 FY2024 | $481.0K | -99.7% | $-49.1M | -10205.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $481000 | $356000 | $49.4M | $7.6M | $6.4M | $18.3M | $581000 | $14.2M |
| YoY Growth | -99.7% | -94.8% | 425.8% | 269.8% | 1238.3% | 5042.1% | -98.8% | 88.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $129.0M | $93.0M | $111.3M | $101.6M | $86.2M | $97.6M | $88.6M | $59.7M |
| Liabilities | $72.3M | $69.3M | $72.1M | $78.9M | $81.3M | $78.0M | $82.4M | $74.0M |
| Equity | $56.7M | $23.7M | $39.1M | $22.8M | $4.9M | $19.6M | $6.2M | $-14.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-48.7M | $-26.9M | $11.8M | $-67.1M | $-26.1M | $-18.2M | $-28.5M | $-97.2M |